Getting latest data loading

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

GSK Page 9

GlaxoSmithKline (GSK)

Will GSK return to July highs of 1640p (+9.7%) or return to September lows of 1440p (-3.7%)?
  • The pharma giant has bounced from 1440p support, breaking out from 2-month falling highs resistance
  • RSI remains stubbornly below the 50 mark, while Stochastics have recovered sharply from oversold
  • Momentum remains negative but close to breakeven, while Directional Indicators close to bullish cross
  • Brokers are overwhelmingly positive, with 92% expecting the price to rally above the current level

 

Broker Consensus: 39% Buy, 52% Hold, 9% Sell

Bullish: Oddo BHF, Outperform, Target 2100p, +40% (29 Sept)

Average Target: 1707p, +14% (29 Sept)

Bearish: Societe Generale, Sell, Target 1250p, -16% (1 Sept)

 

Pricing data sourced from Bloomberg on 29 September. Please contact us for a full, up to date rundown.

« Back to Category

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.

Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research

Comments are closed.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.